All In Biotech

Drug Trial Radar · NCT00030719

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

High Risk Neuroblastoma Study 1 Of Siop-Europe

Last checked: Nov 20, 2026Latest source record: Jun 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

175

Planned (sponsor's estimate)

Start

Dec 2001

Primary completion

Not stated

Sponsor

Lead sponsor
University of LeicesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining isotretinoin and monoclonal antibodies may kill any remaining tumor cells following surgery. It is not yet known which treatment regimen is more effective in treating neuroblastoma. PURPOSE: This randomized phase III trial is studying how well combination chemotherapy with or without filgrastim before surgery, high-dose chemotherapy, and radiation therapy followed by isotretinoin with or without monoclonal antibody work in treating patients with neuroblastoma.

Conditions

  • Neuroblastoma

Interventions

  • filgrastimBiological

  • monoclonal antibody Ch14.18Biological

  • busulfanDrug

  • carboplatinDrug

  • cyclophosphamideDrug

  • etoposideDrug

  • isotretinoinDrug

  • melphalanDrug

  • vincristine sulfateDrug

  • bone marrow ablation with stem cell supportProcedure

  • conventional surgeryProcedure

  • peripheral blood stem cell transplantationProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival at 3 years
  2. Mean number of febrile events during induction

Locations

32 sites in 13 countries. Site status is shown where the registry gives one.

  • St. Anna Children's Hospital

    Vienna, Austria · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • Aarhus Universitetshospital - Aarhus Sygehus

    Aarhus, Denmark · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Our Lady's Hospital for Sick Children Crumlin

    Dublin, Ireland · Recruiting

  • Schneider Children's Medical Center of Israel

    Petah Tikva, Israel · Recruiting

  • Fondazione Istituto Nazionale dei Tumori

    Milan, Italy · Recruiting

  • Rikshospitalet University Hospital

    Oslo, Norway · Recruiting

  • Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, SA

    Lisbon, Portugal · Recruiting

  • Hospital Universitario La Fe

    Valencia, Spain · Recruiting

  • Karolinska University Hospital - Solna

    Stockholm, Sweden · Recruiting

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Switzerland · Recruiting

  • Birmingham Children's Hospital

    Birmingham, England, United Kingdom · Recruiting

  • Institute of Child Health at University of Bristol

    Bristol, England, United Kingdom · Recruiting

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom · Recruiting

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom · Recruiting

  • Leicester Royal Infirmary

    Leicester, England, United Kingdom · Recruiting

  • Royal Liverpool Children's Hospital, Alder Hey

    Liverpool, England, United Kingdom · Recruiting

  • Middlesex Hospital

    London, England, United Kingdom · Recruiting

  • Great Ormond Street Hospital for Children

    London, England, United Kingdom · Recruiting

  • Royal Manchester Children's Hospital

    Manchester, England, United Kingdom · Recruiting

  • Sir James Spence Institute of Child Health at Royal Victoria Infirmary

    Newcastle upon Tyne, England, United Kingdom · Recruiting

  • Queen's Medical Centre

    Nottingham, England, United Kingdom · Recruiting

  • Oxford Radcliffe Hospital

    Oxford, England, United Kingdom · Recruiting

  • Children's Hospital - Sheffield

    Sheffield, England, United Kingdom · Recruiting

  • Southampton General Hospital

    Southampton, England, United Kingdom · Recruiting

  • Royal Marsden - Surrey

    Sutton, England, United Kingdom · Recruiting

  • Royal Belfast Hospital for Sick Children

    Belfast, Northern Ireland, United Kingdom · Recruiting

  • Royal Aberdeen Children's Hospital

    Aberdeen, Scotland, United Kingdom · Recruiting

  • Royal Hospital for Sick Children

    Edinburgh, Scotland, United Kingdom · Recruiting

  • Royal Hospital for Sick Children

    Glasgow, Scotland, United Kingdom · Recruiting

  • Childrens Hospital for Wales

    Cardiff, Wales, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.